UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  May 17, 2012
 
LANTHEUS MEDICAL IMAGING, INC.
(Exact name of registrant as specified in its charter)
 
Delaware	 	333-169785	 	51-0396366	
(State or other jurisdiction of incorporation)	 	(Commission File Number)	 	(IRS Employer Identification No.)	
 
331 Treble Cove Road, North Billerica, MA 01862
(Address of principal executive offices) (Zip code)
 
Registrant’s telephone number, including area code:  (978) 671-8001
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
Item 8.01                                          Other Events
 
A copy of Lantheus Medical Imaging, Inc’s press release, dated May 17, 2012, announcing the appointment of Samuel R. Leno to the Board of Directors of Lantheus MI Holdings, Inc., the indirect parent of Lantheus Medical Imaging, Inc., is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01                                          Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit
Number	 	Description of Exhibits	
99.1	 	Press Release, dated May 17, 2012, announcing the appointment of Samuel R. Leno.	
 
2

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	LANTHEUS MEDICAL IMAGING, INC.	
 	 	
 	By:	/s/ Michael P. Duffy	
 	Name:	Michael P. Duffy	
 	Title:	Vice President and General Counsel	

Date: May 17, 2012
 
3

 
EXHIBIT INDEX
 
Exhibit
Number	 	Description of Exhibits	
99.1	 	Press Release, dated May 17, 2012, announcing the appointment of Samuel R. Leno.	
 
4

Exhibit 99.1

 
FOR IMMEDIATE RELEASE
 
CONTACTS:
 
Lantheus Medical Imaging	Pure Communications	
Linda Lennox	Michele Rozen	
978-671-8854	617-730-8284	
 
Meara Murphy
978-671-8508
 
Lantheus Appoints New Member to its Board of Directors
 
Addition of Samuel R. Leno Further Enhances Board’s Financial Expertise
 
No. BILLERICA, Mass. (May 17, 2012) — Lantheus MI Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the appointment of Samuel R. Leno as a member of its Board of Directors.
 
Mr. Leno, who will also serve as the Chairman of the Audit Committee of the Board, is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011.
 
Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. Mr. Leno previously held a number of financial leadership positions at Arrow Electronics, Inc., Corporate Express, Inc., Coram Healthcare and Baxter International, Inc.
 
“Sam is a seasoned executive with a track record of success and we are pleased to welcome him to the Board of Directors,” said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging. “Sam’s extensive financial and operational experience will be a great asset to our board and to the Company’s strategic planning and operations.”
 
“I am honored to join the Lantheus board and work with their exceptional team,” said Mr. Leno. “Lantheus has been an innovative leader in diagnostic imaging for decades, and I look forward to playing an important role on the Lantheus board as we implement the Company’s strategy for the future.”
 
1

 
Mr. Leno recently served on the Board of Directors and as a member of the Audit Committee of TomoTherapy, Inc., and is also a member of the Advisory Board of the Harvard Business School Healthcare Initiative. He received a B.S. degree in Accounting from Northern Illinois University and an M.B.A. from Roosevelt University. In addition, prior to beginning his business career, he served as a U.S. Naval Officer and is a Vietnam veteran.
 
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY ®  Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border; ABLAVAR ®  (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease; TechneLite ®  (Technetium Tc99m Generator), Cardiolite ®  (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
 
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
 
# # #
 
2